Finally, in order to examine whether response to PARP inhibition in primary human leukemia cells is STAG2 mutation dependent, we treated STAG2-mutant and WT primary AML patient samples with talazoparib and noted a dose- and genotype-dependent sensitivity to the drug (Supplemental Figure 3D). This evidence concerns the gene STAG2 and leukemia.